Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.58 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.58 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorbitololeic Acid SCHEMBL3268606 | 1.00 | DGKA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Sorbitololeic Acid SCHEMBL30331597 | 1.00 | DGKA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Sorbitololeic Acid SCHEMBL41613 | 1.00 | DGKA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL11046699 | 0.97 | DGKA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL1795164 | 0.97 | DGKA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL6149779 | 0.96 | FAAH (0.69) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Sorbitololeic Acid SCHEMBL11211814 | 0.94 | DGKA (0.69) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Sorbitololeic Acid SCHEMBL6112163 | 0.94 | DGKA (0.65) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Glyceryl Monooleate SCHEMBL27704769 | 0.92 | DGKA (0.87) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL8188858 | 0.92 | DGKA (0.77) | DGKAPRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149309-A1 | COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USES | SHARED VISION TECHNOLOGY LTD. (IE) | 2023-05-18 | — | — | US | disclosed |
| EP-4117633-A1 | COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USES | SHARED VISION TECHNOLOGY LTD. (IE) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021191462-A1 | COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USES | SHARED VISION TECHNOLOGY LTD. (IE) | 2021-09-30 | — | — | WO | disclosed |
| US-9687551-B2 | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160271255-A1 | COMPOSITIONS COMPRISING LECITHIN OILS AND NSAIDS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160220679-A1 | COMPOSITIONS COMPRISING LECITHIN OILS AND NSAIDS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | UNIV TEXAS (US) | 2016-08-04 | — | — | US | disclosed |
| US-9351984-B2 | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-31 | — | — | US | disclosed |
| US-9101637-B2 | Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150011507-A1 | COMPOSITIONS COMPRISING LECITHIN OILS AND NSAIDS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-01-08 | — | — | US | disclosed |
| US-8911752-B2 | Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-12-16 | — | — | US | disclosed |
| US-20110065677-A1 | Methods of Treating Inflammation with Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastrointestinal Tract and Providing Enhanced Therapeutic Activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110034568-A1 | Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100173876-A1 | OIL-BASED NSAID COMPOSITIONS AND METHODS FOR MAKING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | disclosed |
| EP-1343529-B1 | NSAID FORMULATIONS COMPRISING LECITHIN OILS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | UNIV TEXAS (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1804766-A2 | PURIFIED PHOSPHOLIPID-NON-STEROIDAL ANTI-INFLAMMATORY DRUG ASSOCIATED COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044377-A2 | PURIFIED PHOSPHOLIPID-NON-STEROIDAL ANTI-INFLAMMATORY DRUG ASSOCIATED COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060078574-A1 | Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2006-04-13 | — | — | US | disclosed |
| US-20040077604-A1 | Reducing toxicity of nonsteroidal antiinflammatory drugs (NSAIDs) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-22 | — | — | US | disclosed |
| EP-1343529-A2 | NSAID FORMULATIONS COMPRISING LECITHIN OILS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | The Board of Regents, The University of Texas System (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002085414-A2 | NSAID FORMULATIONS COMPRISING LECITHIN OILS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078574-A1 | Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same | PHOSPHO1, PLTP, PLA2G7 | DGKA 1119/4885PRKCA 3105/4885PRKCE 3011/4885 |
| US-20100173876-A1 | OIL-BASED NSAID COMPOSITIONS AND METHODS FOR MAKING AND USING SAME | ALOX5, ALOX15, PTGES | DGKA 412/4885PRKCA 1995/4885PRKCE 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.